Novo Nordisk A/S: Hemorrhage trials

The registry lists 29 Hemorrhage studies with Novo Nordisk A/S as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 2Phase 2 11Phase 3 10Phase 4 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks PeriodCompletedNCT03449342Phase 4Results posted
• Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia ACompletedNCT02938585Phase 3Results posted
• Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia ACompletedNCT01480180Phase 3Results posted
• Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and InhibitorsCompletedNCT01392547Phase 3Results posted
• Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B PatientsCompletedNCT01333111Phase 3Results posted
• Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015CompletedNCT00984126Phase 3Results posted
• Safety and Efficacy of Turoctocog Alfa in Haemophilia A SubjectsCompletedNCT00840086Phase 3Results posted
• Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited DeficiencyCompletedNCT00713648Phase 3Results posted
• Evaluation of Recombinant Factor VIIa in Patients With Severe BleedingTerminatedNCT00184548Phase 3Results posted
• Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of BernCompletedNCT04444856
• Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral HaemorrhageCompletedNCT01566786Phase 2
• Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell TransplantationTerminatedNCT01564563Phase 2
• Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma PatientsCompletedNCT01563523Phase 2
• Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver TransplantationCompletedNCT01563458Phase 2
• Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral HaemorrhageCompletedNCT01563445Phase 2
• Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell TransplantationCompletedNCT01562158Phase 2
• Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male SubjectsCompletedNCT01561417Phase 1
• Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired HaemophiliaCompletedNCT01285089
• Observational Study to Investigate the Occurrence of Bleeding in Postmenopausal Women Treated With Estradiol/NETA for 12 MonthsCompletedNCT01076621
• Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IXCompletedNCT00710619
• Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in GermanyCompletedNCT00697320
• Recombinant Factor VIIa in Acute Intracerebral HaemorrhageCompletedNCT00426803Phase 2
• Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to TraumaWithdrawnNCT00323570Phase 3
• Factor VIIa in Acute Intracerebral HaemorrhageCompletedNCT00266006Phase 2
• Use of NovoSeven® in Active Variceal BleedingCompletedNCT00154492Phase 2
• Use of Activated Recombinant Human Factor VII in Cardiac SurgeryTerminatedNCT00154427Phase 2
• Recombinant Factor VIIa in Acute Intracerebral HaemorrhageCompletedNCT00127283Phase 3
• Efficacy of NovoSeven® in Bleeding Prophylaxis in HemophiliaCompletedNCT00108758Phase 2
• Dose Response to Recombinant Factor VIIa When Administered for BleedCompletedNCT00104455Phase 1